Pharvaris NVFRA:9EN -1.76%28 PB Ratio is 8.50 as of Jul. 11, 2026. GuruFocus rates FRA:9EN with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, Pharvaris NV ranks worse than 82.8% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-11), Pharvaris NV's share price is €30.70. Pharvaris NV's Book Value per Share for the quarter that ended in Mar. 2026 was €3.61. Hence, Pharvaris NV's PB Ratio of today is 8.50.
The historical rank and industry rank for Pharvaris NV's PB Ratio or its related term are showing as below:
FRA:9EN'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 8.6
Current: 8.45
During the past 9 years, Pharvaris NV's highest PB Ratio was 8.60. The lowest was 0.00. And the median was 0.00.
FRA:9EN's PB Ratio is ranked worse than 82.8% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs FRA:9EN: 8.45
During the past 12 months, Pharvaris NV's average Book Value Per Share Growth Rate was -5.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.40% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Pharvaris NV was 235.50% per year. The lowest was -9.60% per year. And the median was 59.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Pharvaris NV PB Ratio Related Terms
Pharvaris NV PB Ratio Historical Data
* Premium members only.
The historical data trend for Pharvaris NV's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharvaris NV's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharvaris NV PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharvaris NV's PB Ratio distribution charts can be found below:
* The bar in red indicates where Pharvaris NV's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Pharvaris NV's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Pharvaris NV (FRA:9EN) has a PB Ratio of 8.50 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pharvaris NV and its competitors. According to the industry distribution chart, Pharvaris NV ranks #1016 out of 1227 companies in the Biotechnology industry, placing it in the top 82.8%.
Is Pharvaris NV's PB Ratio too high?
Pharvaris NV's current PB Ratio is 8.50. The Biotechnology industry median PB Ratio is 2.95. Pharvaris NV's value of 8.50 is 188.1% above this industry median. Based on the distribution chart, Pharvaris NV ranks #1016 out of 1227 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharvaris NV has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's PB Ratio compare to BHVN and NRIX?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #1016 out of 1227 companies for PB Ratio. This places Pharvaris NV in the lower half of its industry. The industry median PB Ratio is 2.95. Pharvaris NV's value of 8.50 is 188.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharvaris NV's current PB Ratio of 8.50 is 188.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pharvaris NV and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharvaris NV's current PB Ratio is 8.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (FRA:9EN) has a current PB Ratio of 8.50. The current PB Ratio is 8.50 and 188.1% above the Biotechnology industry median of 2.95. Pharvaris NV's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Pharvaris NV (FRA:9EN), the current PB Ratio is 8.50 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
28GF Score
Get the complete analysis for FRA:9EN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9EN has been successfully added to your 
